← All trials
NCT06881264
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2024
- Primary completion
- Aug 15, 2025
- Completion date
- Sep 22, 2025
- First posted
- Mar 18, 2025
- Last posted
- Jul 3, 2025
- Enrollment
- 401
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hengrui Therapeutics, Inc.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.